Details:

Personal Author:
O’Shea, Jesse ; Filardo, Thomas D. ; Morris, Sapna Bamrah ; Weiser, John ; Petersen, Brett ; ... More +
O’Shea, Jesse ; Filardo, Thomas D. ; Morris, Sapna Bamrah ; Weiser, John ; Petersen, Brett ; Brooks, John T. Less -
Corporate Authors:
CDC Monkeypox Response. ; Centers for Disease Control and Prevention (U.S.). Epidemic Intelligence Service.
CDC Monkeypox Response. ; Centers for Disease Control and Prevention (U.S.). Epidemic Intelligence Service. Less -
Description:
What is already known about this topic? A multinational monkeypox outbreak disproportionately affecting men who have sex with men, including persons with HIV infection, is ongoing worldwide.

What is added by this report? CDC has developed clinical considerations for prevention and treatment of monkeypox in persons with HIV infection, including pre-exposure and postexposure prophylaxis with JYNNEOS vaccine, treatment with tecovirimat, and infection control.

What are the implications for public health practice? Persons with advanced HIV might be at increased risk for severe monkeypox. Postexposure prophylaxis and antiviral treatments are available for persons with HIV infection. Prompt diagnosis and treatment and enhanced prevention efforts might reduce the risk for severe outcomes.

Monkeypox virus, an orthopoxvirus sharing clinical features with smallpox virus, is endemic in several countries in Central and West Africa. The last reported outbreak in the United States, in 2003, was linked to contact with infected prairie dogs that had been housed or transported with African rodents imported from Ghana (1). Since May 2022, the World Health Organization (WHO) has reported a multinational outbreak of monkeypox centered in Europe and North America, with approximately 25,000 cases reported worldwide; the current outbreak is disproportionately affecting gay, bisexual, and other men who have sex with men (MSM) (2). Monkeypox was declared a public health emergency in the United States on August 4, 2022.† Available summary surveillance data from the European Union, England, and the United States indicate that among MSM patients with monkeypox for whom HIV status is known, 28%–51% have HIV infection (3–10). Treatment of monkeypox with tecovirimat as a first-line agent is available through CDC for compassionate use through an investigational drug protocol. No identified drug interactions would preclude coadministration of tecovirimat with antiretroviral therapy (ART) for HIV infection. Pre- and postexposure prophylaxis can be considered with JYNNEOS vaccine, if indicated. Although data are limited for monkeypox in patients with HIV, prompt diagnosis, treatment, and prevention might reduce the risk for adverse outcomes and limit monkeypox spread. Prevention and treatment considerations will be updated as more information becomes available.

Suggested citation for this article: O’Shea J, Filardo TD, Morris SB, Weiser J, Petersen B, Brooks JT. Interim Guidance for Prevention and Treatment of Monkeypox in Persons with HIV Infection — United States, August 2022. MMWR Morb Mortal Wkly Rep. ePub: 5 August 2022.

mm7132e4.htm?s_cid=mm7132e4_w

mm7132e4-H.pdf


Subjects:
[+]
Coinfection HIV Infections Mpox (monkeypox)
Series:
MMWR. Morbidity and mortality weekly report ; v. 71, early release, August 5, 2022
Document Type:
Journal Article
Collection(s):
Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:
[+]
urn:sha256:da2d605e3e651c894f17282bb27d106af6d53122afa5b2eaeae185d7c36c905c
Download URL:
https://stacks.cdc.gov/view/cdc/119937/cdc_119937_DS1.pdf
File Type:

Supporting Files

• mm7132e4.htm?s_cid=mm7132e4_w

  htm

More +